NASDAQ:BYSIBeyondspring Stock Price, Forecast & News

Beyondspring's stock was trading at $11.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BYSI stock has increased by 30.1% and is now trading at $14.77. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beyondspring in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Beyondspring.

Beyondspring is scheduled to release its next quarterly earnings announcement on Wednesday, September 16th 2020. View our earnings forecast for Beyondspring.

Beyondspring Inc (NASDAQ:BYSI) released its quarterly earnings data on Thursday, June, 11th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.50) by $0.08. View Beyondspring's earnings history.

4 analysts have issued twelve-month price targets for Beyondspring's shares. Their forecasts range from $25.00 to $46.00. On average, they expect Beyondspring's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 137.0% from the stock's current price. View analysts' price targets for Beyondspring.

Press coverage about BYSI stock has trended somewhat negative on Friday, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Beyondspring earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Beyondspring.

Some companies that are related to Beyondspring include Aurinia Pharmaceuticals (AUPH), Madrigal Pharmaceuticals (MDGL), Passage Bio (ZNTL), Akebia Therapeutics (AKBA), I-Mab (IMAB), INDIVIOR PLC/S (INVVY), Intra-Cellular Therapies (ITCI), Y-mAbs Therapeutics (YMAB), Zymeworks (ZYME), Ironwood Pharmaceuticals (IRWD), Zogenix (ZGNX), Epizyme (EPZM), Intercept Pharmaceuticals (ICPT), BELLUS Health (BLUSF) and Mersana Therapeutics (MRSN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Beyondspring investors own include Exelixis (EXEL), Enterprise Products Partners (EPD), Intel (INTC), AbbVie (ABBV), Gilead Sciences (GILD), Johnson & Johnson (JNJ), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), Crispr Therapeutics (CRSP) and Enbridge (ENB).

(BYSI) raised $4 million in an initial public offering on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO.

Beyondspring trades on the NASDAQ under the ticker symbol "BYSI."

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BYSI stock can currently be purchased for approximately $14.77.

Beyondspring has a market capitalization of $444.70 million. The company earns $-38,080,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

The official website for Beyondspring is www.beyondspringpharma.com.

Beyondspring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected]